A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents: The EFA-trial

Thrombosis and Haemostasis

Volumn 104, Issue 3, 2010, Pages 554-562

  Wenaweser, Peter ^a   Eshtehardi, Parham ^a   Abrecht, Linda ^a   Zwahlen, Marcel ^b,c   Schmidlin, Kurt ^b,c   Windecker, Stephan ^a   Meier, Bernhard ^a   Haeberli, Andre ^a   Hess, Otto M ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acetylsalicylic acid; Atorvastatin; Clopidogrel; Coronary stent; Fluvastatin; Platelet aggregation; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WHOLE BLOOD IMPEDANCE PLATELET AGGREGOMETRY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; PYRROLES; SWITZERLAND; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956623528     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-11-0765     Document Type: Article

References (39)

1. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 11: 1748-1752.
2. Heller LI, Shemwell KC, Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 2001; 1: 23-28.
3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 10: 1030-1039.
4. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 10: 1020-1029. (Pubitemid 46376802)
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 10: 998-1008.
6. Windecker S, Juni P. Safety of drug-eluting stents. Nat Clin Pract Cardiovasc Med 2008; 6: 316-328.
7. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 17: 1952-1965.
8. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation 2003; 1: 2-5.
9. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 17: 2126-2130.
10. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 10: 1820-1826.
11. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 10: 1827-1832.
12. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 1: 32-37.
13. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003; 19: 1744-1749. (Pubitemid 37236863)
14. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 1: 53-59.
15. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 8: 921-924.
16. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 3: 285-288.
17. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 21: 1898-1902.
18. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 11: 1335-1338.
19. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004; 18: 2051-2057.
20. Mukherjee D, Kline-Rogers E, Fang J, et al. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005; 1: 23-26. (Pubitemid 39664985)
21. Geisler T, Zurn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008; 13: 1635-1643.
22. Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 1: 174-181.
23. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 8: 804-847.
24. Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005; 8: 476-481. (Pubitemid 41153201)
25. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003; 3: 307-317.
26. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer - comparison with two flow cytometric methods. Thromb Res 2007; 2: 249-258.
27. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 1: 121-126.
28. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 2: 333-339.
29. Siller-Matula JM, Gouya G, Wolzt M, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 2009; 2: 397-403.
30. Wenaweser P, Windecker S, Billinger M, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007; 3: 353-356.
31. Osamah H, Mira R, Sorina S, et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 1: 77-83.
32. Haramaki N, Ikeda H, Takenaka K, et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 2007; 6: 1471-1477.
33. Ayalasomayajula SP, Vaidyanathan S, Kemp C, et al. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. J Clin Pharmacol 2007; 5: 613-619. (Pubitemid 46632152)
34. Smith SM, Judge HM, Peters G, et al. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004; 8: 465-474.
35. Winkler K, Abletshauser C, Friedrich I, et al. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 2004; 3: 1153-1159.
36. Vinholt P, Poulsen TS, Korsholm L, et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005; 2: 438-443.
37. Riondino S, Petrini N, Donato L, et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis 2009; 2: 151-155.
38. Gurbel PA, Bliden KP, Etherington A, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 1: 107-115. (Pubitemid 350025991)
39. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 11: 2516-2518.